DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
GC4419 is an investigational drug.
There have been 9 clinical trials for GC4419. The most recent clinical trial was a Phase 1 trial, which was initiated on October 3rd 2018.
The most common disease conditions in clinical trials are Stomatitis, Mucositis, and Head and Neck Neoplasms. The leading clinical trial sponsors are Galera Therapeutics, Inc., INC Research, and Clinical Assistance Programs, LLC.
There are two US patents protecting this investigational drug and thirteen international patents.
Recent Clinical Trials for GC4419
|Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects||Galera Therapeutics, Inc.||Phase 1|
|ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer||Galera Therapeutics, Inc.||Phase 3|
|Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer||M.D. Anderson Cancer Center||Phase 1/Phase 2|
Top disease conditions for GC4419
Top clinical trial sponsors for GC4419
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GC4419||Start Trial||Methods for treatment of diseases||GALERA LABS, LLC (Creve Coeur, MS)||Start Trial|
|GC4419||Start Trial||Methods for treatment of diseases||GALERA LABS, LLC (Creve Coeur, MO)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|